Revlimid – the key concern for Dr Reddy’s is due to the drug’s patent expiry in January 2026, paving the way for competition from generic makers and reduced prices.
Revlimid – the key concern for Dr Reddy’s is due to the drug’s patent expiry in January 2026, paving the way for competition from generic makers and reduced prices.